



Council of the
European Union

Brussels, 14 December 2016
(OR. en)

15562/16

CORDROGUE 86
SAN 433

COVER NOTE

From:	Matthias Ruete
date of receipt:	25 November 2016
To:	Ambassador Peter Javorčík
Subject:	Request for risk assessment on new psychoactive substance <i>N</i> -(1-phenethylpiperidin-4-yl)- <i>N</i> -phenylacrylamide (acryloylfentanyl)

Delegations will find attached a request from the Commission for a risk assessment on new psychoactive substance *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylacrylamide (acryloylfentanyl).



EUROPEAN COMMISSION
DIRECTORATE-GENERAL MIGRATION and HOME AFFAIRS

The Director-General

Brussels, 25 November 2016
DG HOME/D3/ARES(2016)7139337

Your Excellency,

On 16 November 2016, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol presented to the Council, the Commission and the European Medicines Agency a Joint Report on the new psychoactive substance acryloylfentanyl. This Joint Report, drawn up in accordance with Article 5(1) of the Council Decision on the information exchange, risk assessment and control of new psychoactive substances¹, provides an overview of the available information on detections, patterns of use and incidents reported on this substance.

According to the Joint Report, 42 deaths associated with acryloylfentanyl have been reported by four Member States. In 29 of these deaths acryloylfentanyl was the cause of death or contributed to the death. All deaths occurred in 2016; 80% of them occurred in a period of three months.

I therefore consider that the health and social risks posed by the manufacture, trafficking and use of acryloylfentanyl, as well as the involvement of organised crime and possible consequences of control measures, should be assessed through a risk assessment, as foreseen by Article 6 of the Council Decision 2005/387/JHA.

His Excellency
Ambassador Peter JAVORČÍK
Permanent Representative of the Slovak Republic to the European Union
107 Avenue de Cortenbergh
1040 Bruxelles
Belgium

¹ OJ L 127, 20.5.2005, p. 32.

I should be grateful if you would notify this request to conduct risk assessment on acryloylfentanyl to the Members of the Council and the Horizontal Drugs Group.

Yours faithfully,



Mathias RUETE

Annex 1: EMCDDA-Europol Joint report acryloylfentanyl, prepared in accordance with Article 5 of Council Decision 2005/387/JHA.

Annex 2: Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances.

Copy: Ms Christine Roger, Director-General, Secretariat General of the Council
Ms Diane Schmitt, Head of Cabinet of Commissioner Avramopoulos
Mr Konstantinos Chatzifotis, Member of Cabinet of Commissioner Avramopoulos